Analysis the expression of SCGB2A2 in the tissues and plasma of breast carcinoma

Objective To investigate the expression of SCGB2A2 in the tissues and plasma of breast carcinoma and clinical value on pulmonary metastatic breast carcinoma. Methods The expression of SCGB2A2 protein was examined in 31 cases of primary breast carcinoma,48 patients with pulmonary metastatic breast carcinoma,39 cases of pulmonary metastatic adenocarcinom other than breast origin pathologically confirmed by immunohistochemical staining technique. The SCGB2A2 level was detected in 87 patients with breast carcinoma,26 cases of mammary fibroadenoma and 30 healthy volunteers by enzyme-linked immunosorbent assay( ELISA). Results SCGB2A2 was positively expressed in 64. 5% of breast carcinoma, higher than that of other origins,and was not detected in other adenocarcinomas. Twenty-six of thirty-eight patients with pulmonary metastatic breast carcinoma were tested SCGB2A2 by immunohistochemistry. However,no expression of SCGB2A2 was detected in pulmonary metastatic adenocarcinom tissue specimens. Its sensitivity and specificity were 63. 9% and 81. 8%,respectively in differential diagnosis of pulmonary metastatic breast carcinoma and pulmonary metastatic adenocarcinom. The SCGB2A2 level in patients with breast carcinoma was significantly higher than that of patients with mammary fibroadenoma and healthy volunteers( P 0. 05). Conclusions SCGB2A2 could be promsing biomarker for differential diagnosis of pulmonary metastatic breast carcinoma for its higher level in primary breast carcinoma than that in primary pulmonary carcinoma. The rising of SCGB2A2 in peripheral blood could be assessed as a marker in detecting microme-tastases for breast carcinoma.